Cytosorbents Corporation CTSO
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.07% | 5.28% | 4.12% | 23.89% | 20.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.07% | 5.28% | 4.12% | 23.89% | 20.18% |
| Cost of Revenue | -8.72% | -2.93% | -1.27% | 74.01% | 87.01% |
| Gross Profit | 8.63% | 9.05% | 6.44% | 10.37% | 2.83% |
| SG&A Expenses | 1.27% | 6.78% | 4.94% | -9.36% | -12.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.20% | -1.28% | -1.88% | -4.70% | -7.05% |
| Operating Income | 23.94% | 15.88% | 14.69% | 41.00% | 38.57% |
| Income Before Tax | -61.05% | 31.18% | 61.62% | 39.82% | 57.14% |
| Income Tax Expenses | 76.29% | 76.29% | 76.29% | -157.10% | -107.82% |
| Earnings from Continuing Operations | -84.58% | 26.44% | 60.43% | 47.94% | 62.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -84.58% | 26.44% | 60.43% | 47.94% | 62.27% |
| EBIT | 23.94% | 15.88% | 14.69% | 41.00% | 38.57% |
| EBITDA | 25.65% | 17.13% | 15.73% | 43.73% | 40.89% |
| EPS Basic | -59.06% | 35.50% | 65.45% | 52.46% | 66.18% |
| Normalized Basic EPS | -30.19% | 44.69% | 70.57% | 47.22% | 62.50% |
| EPS Diluted | -58.11% | 35.33% | 65.25% | 52.29% | 66.04% |
| Normalized Diluted EPS | -28.90% | 44.03% | 70.06% | 46.70% | 62.13% |
| Average Basic Shares Outstanding | 8.00% | 11.91% | 14.22% | 14.81% | 16.45% |
| Average Diluted Shares Outstanding | 5.92% | 13.94% | 16.31% | 16.98% | 18.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |